Analysis of commercially available snake antivenoms reveals high contents of endotoxins in some products
Guardado en:
| Autores: | , , , , , , , |
|---|---|
| Format: | artículo original |
| Fecha de Publicación: | 2024 |
| Beskrivelse: | As injectable therapeutics, snake antivenoms must meet specifications for endotoxin content. The Limulus amebocyte lysate (LAL) test was used to evaluate the endotoxin content in several commercially available antivenoms released for clinical use. It was found that some products have endotoxin concentrations higher than the accepted limit for these contaminants. These results emphasize the need to include endotoxin determination as part of the routine evaluation of antivenoms by manufacturers and regulatory agencies. |
| País: | Kérwá |
| Institution: | Universidad de Costa Rica |
| Repositorio: | Kérwá |
| Sprog: | Inglés |
| OAI Identifier: | oai:kerwa.ucr.ac.cr:10669/103237 |
| Online adgang: | https://www.sciencedirect.com/science/article/pii/S2590171024000043 https://hdl.handle.net/10669/103237 https://doi.org/10.1016/j.toxcx.2024.100187 |
| Palabra clave: | Endotoxin Limulus amebocyte lysate test Snake antivenom Pyrogen |